Etude visant à évaluer le lutécium (¹⁷⁷Lu) vipivotide tétraxétan chez des patients atteints de cancer de la prostate métastatique progressif, résistant à la castration (CPRCm) et présentant une insuffisance rénale modérée ou sévère ou une fonction rénale normale

Patients atteints de cancer de la prostate métastatique, progressif, résistant à la castration, positif pour l’antigène membranaire spécifique de la prostate (PSMA pour prostate-specific membrane antigen), et présentant une :
- Insuffisance rénale modérée
-Insuffisance rénale sévère
- Fonction rénale normale

Assessment of the ¹⁸F-florbetaben whole-body PET imaging diagnostic performance for the detection of cardiac and extracardiac sites of amyloid deposits in patients with amyloidosis

Amyloidosis

Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [¹⁸F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor

Parkinson et Tremblement Essentiel

A multicenter, open-label, non-randomized Phase 1/2 study to assess safety,tolerability, and imaging characteristics of [⁶⁸Ga]Ga-DPI-4452 and to assess safety, tolerability, and efficacy of [¹⁷⁷Lu]Lu-DPI-4452 in patients with unresectable locally advanced or metastatic solid tumors

Histologically or cytologically confirmed, unresectable locally advanced or metastatic solid tumors of:
- ccRCC: patients must have received at least one line containing TKI treatment and at least one line containing Immune Checkpoint Inhibitor treatment in metastatic setting, meaning at least two lines of treatment in metastatic setting; or
- PDAC: patients must have received at least one line of platinum- and/or gemcitabine-based regimen; or
- CRC: patients must have received at least one line of FOLFIRINOX or FOLFOX/FOLFIRI in two lines in combination with anti-VEGF or anti-EGFR

A multicenter, open-label, non-randomized Phase 1/2 study to assess safety,tolerability, and imaging characteristics of [⁶⁸Ga]Ga-DPI-4452 and to assess safety, tolerability, and efficacy of [¹⁷⁷Lu]Lu-DPI-4452 in patients with unresectable locally advanced or metastatic solid tumors

Histologically or cytologically confirmed, unresectable locally advanced or metastatic solid tumors of:
- ccRCC: patients must have received at least one line containing TKI treatment and at least one line containing Immune Checkpoint Inhibitor treatment in metastatic setting, meaning at least two lines of treatment in metastatic setting; or
- PDAC: patients must have received at least one line of platinum- and/or gemcitabine-based regimen; or
- CRC: patients must have received at least one line of FOLFIRINOX or FOLFOX/FOLFIRI in two lines in combination with anti-VEGF or anti-EGFR

Contribution of Cerebral ¹⁸F-DOPA PET-CT Scan in High-grade Recurrent Gliomas : a Monocentric Pilot Impact Study on the Practices of Defining Target Volumes Before RAdiotherapy

Gliioma

Pilot study evaluating somatostatin receptor PET imaging to detect inflammatory phases of myocarditis

Myocarditis

Early feasibility study of somatostatin receptor PET imaging for the diagnosis of infective endocarditis

Infective endocarditis

Prospective multicenter study to evaluate the diagnostic performance of [¹⁸F]PSMA-1007 PET/CT imaging in patients with newly diagnosed high-risk or very high-risk prostate cancer

Les patients chez qui un cancer de la prostate a été récemment diagnostiqué et pour lesquels il est initialement prévu d'effectuer une chirurgie d'ablation de la prostate et des ganglions lymphatiques pelviens (prostatectomie radicale avec dissection élargie des ganglions lymphatiques pelviens (RP avec EPLND)

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of ¹⁷⁷Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

Evaluation of the addition of Everolimus to ¹⁷⁷Lu-DOTATATE in the treatment of grades 2 and 3 refractory meningioma: a phase IIb clinical trial

Grade 2 and 3 refractory meningioma

Evaluation d’une méthode de dosimétrie en routine clinique en caméra VERITON-CT™ chez des patients traités par Lutathera [¹⁷⁷Lu- [DOTA0, Tyr3] -octréotate

Patients receiving Luthatera ® therapy

Optimized Imaging of Fibrosis and Intestinal Inflammation in Crohn's Disease

Crohn's disease

GATED cardiac analysis in patients with ⁶⁸GA-DOTATOC PET for oncological indications

Diagnostic or pre-therapeutic workup or follow-up of a neuroendocrine tumor

Randomized controlled trial evaluating the efficacy of HYpnosis using a DEported method adapted to Nuclear Medicine versus hypnosis using a conventional method

Ericksonian hypnosis session given to patients during a scintigraphic or PET examination in a remote setting

Evaluation of diagnostic performances of ¹⁸F-FDOPA PET KInetics as biomarkers for the improvement of care of MRI Non-contrast enhanced Gliomas

Suspicion of Glioma with MRI non contrast enhanced

Interest of the combination of ultrasound with Ti-RADS score / dual tracer MIBI-Tc99m/Iodine-123 scintigraphy in the detection of malignancy of thyroid nodules (≥ 15 mm) classified Bethesda III or IV in cytopuncture

Thyroid nodules (≥ 15 mm) classified as Bethesda III or IV on cytopuncture

Contribution of MUltiparametric analysis in bone scintigraphy for the characterization of solitary bone lesions whose malignant origin cannot be excluded on conventional imaging

Patients with solitary bone lesions indeterminate on conventional imaging who are scheduled for biopsy or excision

Diagnostic performance of SPECT/CT bone scan quantification prior to lumbar arthodesis surgery

People with back pain for at least 3 months (presumed to be due to degenerative discarthrosis or spondylolisthesis)

A prospective, post-authorization, multicenter, open-label, non-interventional registry study to evaluate the efficacy of TheraSphere® in clinical practice in France

Unresectable hepatocellular carcinoma (HCC)

An International Prospective Open-label, Randomized, Phase III Study comparing ¹⁷⁷Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

A prospective randomized phase ii study to assess the schemas of retreatment with lutathera® ([¹⁷⁷Lu]lu-dota-tate) in patients with new progression of intestinal well-differentiated neuroendocrine tumor

intestinal well-differentiated neuroendocrine tumor

A Phase I/II, open-label, multi-center study of [²²⁵Ac]Ac-PSMA-R2 in men with heavily pre-treated PSMA positive metastatic castration resistant prostate cancer (mCRPC) with or without prior ¹⁷⁷Lu-labelled PSMAtargeted radioligand therapy

pre-treated PSMA positive metastatic castration resistant prostate cancer (mCRPC)

¹⁸F-FDG PET/CT characterization of brain lesions in young subjects with sequelae of psycho-cognitive disorders in the aftermath of severe Covid-19

Sequelae of psycho-cognitive disorders following severe Covid-19

Évaluation d’une procédure d’enregistrement corps entier 3D en caméra CZT « VERITON-CT™ » : Comparaison à la procédure classique d’enregistrement 2D corps entier associée à des tomoscintigraphies complémentaires chez des patients ayant reçu un traitement par Iode 131 pour un Cancer Thyroïdien

Thyroid cancer patients for whom multidisciplinary consultation meeting has validated iratherapy treatment